Open AccessPathogenetic treatment of the patient with splenic marginal zone lymphoma complicated by Evans syndrome
Author(s) -
Н. А. Романенко,
Романенко Николай Александрович,
С. С. Бессмельцев,
Бессмельцев Станислав Семёнович,
Kudrat Abdulkadyrov,
Абдулкадыров Кудрат Мугутдинович
Publication year - 2012
Publication title -
kazanskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2587-9359
pISSN - 0368-4814
DOI - 10.17816/kmj1726
Subject(s) - medicine , evans syndrome , fludarabine , cyclophosphamide , rituximab , neutropenia , splenic marginal zone lymphoma , autoimmune hemolytic anemia , anemia , lymphoma , marginal zone , surgery , gastroenterology , blood transfusion , chemotherapy , splenectomy , spleen , immunology , antibody , b cell
A case report of a patients with splenic marginal zone lymphoma, in whom clinical remission was initially achieved by 5 continuous courses of combined treatment with fludarabine 25 mg/m2 and cyclophosphamide 350 mg/m2 at days 1-3. Nevertheless, 6 months after patient developed a clinical picture of Evans syndrome, characterized by severe hemolytic anemia, thrombocytopenia and neutropenia. Corticosteroid treatment accompanied by blood transfusion was initiated, the effect was marginal and short-lasting. Switch to rituximab monotherapy allowed to archieve complete clinical and hematological remission with full blood count parameters reversal.